These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29555543)

  • 1. Re: Recent Changes in Prostate Cancer Screening Practices and Epidemiology: D. J. Lee, K. Mallin, A. J. Graves, S. S. Chang, D. F. Penson, M. J. Resnick and D. A. Barocas J Urol 2017;198:1230-1240.
    Patel N; Hu JC
    J Urol; 2018 Jun; 199(6):1633-1634. PubMed ID: 29555543
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study: S. Avulova, Z. Zhao, D. Lee, L. C. Huang, T. Koyama, K. E. Hoffman, R. M. Conwill, X. C. Wu, V. Chen, M. R. Cooperberg, M. Goodman, S. Greenfield, A. S. Hamilton, M. Hashibe, L. E. Paddock, A. Stroup, M. J. Resnick, D. F. Penson and D. A. Barocas J Urol 2018;199:1202-1209.
    Ramakrishnan VM; Bossert K; Lehmann KH; Hefermehl LJ
    J Urol; 2018 Nov; 200(5):1124-1125. PubMed ID: 30059667
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426.
    Moul JW; Walsh PC; Rendell MS; Lynch HT; Leslie SW; Kosoko-Lasaki O; Fitzgibbons WP; Powell I; D'Amico AV; Catalona WJ
    J Urol; 2013 Sep; 190(3):1134-7. PubMed ID: 23871525
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Ureteroenteric anastomotic strictures after radical cystectomy--does operative approach matter?: C. B. Anderson, T. M. Morgan, S. Kappa, D. Moore, P. E. Clark, R. Davis, D. F. Penson, D. A. Barocas, J. A. Smith, Jr., M. S. Cookson and S. S. Chang. J Urol 2013; 189: 541-547.
    Skinner DG
    J Urol; 2013 Jul; 190(1):362-3. PubMed ID: 23416635
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682.
    Shah N; Ioffe V
    J Urol; 2018 Jul; 200(1):202. PubMed ID: 29596802
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Prostate specific antigen working group guidelines on prostate specific antigen doubling time: P. M. Arlen, F. Bianco, W. L. Dahut, A. D'Amico, W. D. Figg, s. J. Freedland, J. L. Gulley, P. W. Kantoff, M. W. Kattan, A. Lee, M. M. Regan and O. Sartor J Urol 2008; 179: 2181-2186.
    Boyd CN
    J Urol; 2009 Jan; 181(1):411; author reply 411. PubMed ID: 19019390
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer: S. Loeb, M. G. Sanda, D. L. Broyles, S. S. Shin, C. H. Bangma, J. T. Wei, A. W. Partin, G. G. Klee, K. M. Slawin, L. S. Marks, R. H. N. van Schaik, D. W. Chan, L. J. Sokoll, A. B. Cruz, I. A. Mizrahi and W. J. Catalona J Urol 2015;193:1163-1169.
    Shah N; Ioffe V
    J Urol; 2015 Dec; 194(6):1825-6. PubMed ID: 26354886
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above: A. Vickers, E. A. Vertosick, D. D. Sjoberg, M. J. Roobol, F. Hamdy, D. Neal, A. Bjartell, J. Hugosson, J. L. Donovan, A. Villers, S. Zappala and H. Lilja J Urol 2017;197:607-613.
    Shah N; Ioffe V
    J Urol; 2017 Aug; 198(2):445-446. PubMed ID: 28457843
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. C. J. Stimson, M. S. Cookson, D. A. Barocas, P. E. Clark, J. E. Humphrey, S. G. Patel, J. A. Smith, Jr. and S. S. Chang. J Urol 2010; 183: 1732-1737.
    Neulander EZ; Katz T; Yusim I; Kaneti J
    J Urol; 2011 Apr; 185(4):1536-7. PubMed ID: 21334665
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265.
    Stenmark MH; Hamstra DA
    J Urol; 2012 Dec; 188(6):2438-9; author reply 2439-40. PubMed ID: 23088984
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Update on AUA guideline on the management of benign prostatic hyperplasia: K. T. McVary, C. G. Roehrborn, A. L. Avins, M. J. Barry, R. C. Bruskewitz, R. F. Donnell, H. E. Foster, Jr., C. M. Gonzalez, S. A. Kaplan, D. F. Penson, J. C. Ulchaker and J. T. Wei J Urol 2011; 185: 1793-1803.
    Abrams P
    J Urol; 2012 Jan; 187(1):358-9; author reply 359. PubMed ID: 22119362
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups: C. B. Anderson, M. R. Kaufman, M. S. Dietrich, D. A. Barocas, S. S. Chang, M. S. Cookson, J. A. Smith, Jr., P. E. Clark and S. D. Herrell J Urol 2012; 187: 1346-1351.
    Namiki S; Arai Y
    J Urol; 2013 Jan; 189(1):394-5. PubMed ID: 23174260
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: re: early detection of prostate cancer: AUA guideline: J. W. Moul, P. C. Walsh, M. S. Rendell, H. T. Lynch, S. W. Leslie, O. Kosoko-Lasaki, W. P. Fitzgibbons, I. Powell, A. V. D'Amico and W. J. Catalona J Urol 2013; 190: 1134-1139.
    Shah N; Ioffe V
    J Urol; 2014 Mar; 191(3):871. PubMed ID: 24355135
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. K. E. Hoffman, P. L. Nguyen, A. K. Ng and A. V. D'Amico. J Urol 2010; 183: 1798-1802.
    Neulander EZ
    J Urol; 2011 May; 185(5):1982; author reply 1983. PubMed ID: 21421243
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: detailed analysis of patients with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institutional study: I. Y. Kim, P. K. Modi, E. Sadimin, Y.-S. Ha, J. H. Kim, D. Skarecky, D. Y. Cha, C. O. Wambi, Y.-C. Ou, B. Yuh, S. Park, E. Llukani, D. M. Albala, T. Wilson, T. Ahlering, K. Badani, H. Ahn, D. I. Lee, M. May, W.-J. Kim and d. H. Lee J Urol 2013;190:527-534.
    Ball MW; Mullins JK; Epstein JI; Partin AW; Walsh PC
    J Urol; 2014 Feb; 191(2):559. PubMed ID: 24239918
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: detailed analysis of patients with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institutional study: I. Y. Kim, P. K. Modi, E. Sadimin, Y.-S. Ha, J. H. Kim, D. Skarecky, D. Y. Cha, C. O. Wambi, Y.-C. Ou, B. Yuh, S. Park, E. Llukani, D. M. Albala, T. Wilson, T. Ahlering, K. Badani, H. Ahn, D. I. Lee, M. May, W.-J. Kim and d. H. Lee J Urol 2013;190:527-534.
    Tuliao PH; Rha KH
    J Urol; 2014 Feb; 191(2):559-60. PubMed ID: 24239915
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Polascik J Urol 2018; 200: 758-766.
    Wang CS; Jhan JH; Li CC
    J Urol; 2019 Mar; 201(3):627-628. PubMed ID: 30759714
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.